Einschätzungen zu Human Genome, Inhale Therap. und Imclone - 500 Beiträge pro Seite

[Chartfan01]

Human Genome Sciences (HGSI)kämpft weiterhin mit der
Widerstandsmarke bei 185U$. Hier kann man ein ansteigendes Dreieck erkennen. Ein Anstieg über 185, dürfte einen schnellen Kursanstieg bis zum Allzeithoch bei 233U$ folgen lassen. Negativ wäre ein Fall unter 150U$.

Inhale Therapeutics Systems (INHL) hat es geschafft die Widerstandsmarke bei 55 U$ zu überwinden und könnte in den kommenden Tagen bis 70U$ steigen. Negativ wird es bei einem Fall unter 50U$.

Imclone (IMCL) hat die Widerstandszone bei 100 U$ hinter sich gelassen und könnte in den kommenden Wochen das All-Time-High in Angriff nehmen. Die Indikatoren sind noch nicht überkauft, so daß hier noch genügend Luft nach oben ist. Ein Fall unter 100U$ (Schlußkurs) würde diese positive Einschätzung zunichte machen.


Gruß
Oliver
www.chartdoc.de

[estephan]

Weiss jemand, warum Human Genome heute so steigt. Gibt es ausser der gestrigen Nachricht weitere News ?

Human Genome vergibt Lizenz an Schering-Plough
Human Genome Sciences (Nasdaq: HGSI) lizenziert ein Protein an Schering-Plough. Das Protein wird normalerweise von Zellen produziert und verhindert die Ausbreitung von Viren im Körper. Schering-Plough wird das Protein als mögliche Behandlung für Krebs, Immunsystemdefekte und Infektionskrankheiten untersuchen

Die Lizenzierung ist das Ergebnis eines 1996 abgeschlossenen Deals, demzufolge Schering-Plough die Option auf die Entwicklung und die Vermarktung von zwei Proteinen erhielt, die mittels der Human Genome-Technologie entdeckt wurden. Human Genome wird durch Prämien für das Erreichen von Zwischenzielen und über Lizenzgebühren an einem möglichen Erfolg des Proteins als Medikament von Schering-Plough entlohnt werden.

Quelle: Comdirect.de

[estephan]

Na ja, schon ein paar Tage alt, stelle es aber trotzdem noch ins Board.

Human Genome mit „Outperform“-Rating

- Das Analystenhaus Lehman Brothers hat in einer erneuten Einstufung Human Genome Sciences von „Neutral“ auf „Outperform“ hochgestuft. „Human Genome hat in letzter zeit große Fortschritte in der Realsierung des Potenzials seiner Genom-Plattform gemacht. Wir sind der Ansicht, dass es das führende Unternehmen im Bereich der Entwicklung von Genom-basierenden Medikamenten ist“, so Lehman Brothers in einer kurzen Stellungsnahme.

Eine Chartanalyse des Human Genome-Papiers zeigt gute Aussichten. Auch die fundamentalen Daten scheinen zu stimmen, sodass die Einstufung von Lehman Brothers durchaus Sinn macht.

Quelle: depotspider.de

[chabambi]

10/16/00 - SmithKline to develop, market repifermin with HGS
ROCKVILLE, Md., Oct 16 (Reuters) - Human Genome Sciences Inc. (HGSI.O) said on Monday SmithKline Beecham Corp. (SB.L) exercised its option to jointly develop and market repifermin, a protein spray found by fishing through the human genome.
The substance is said to help heal large painful sores that plague many elderly patients an represents the company`s first success in using its genetics technology, rather than attempting ti use the genes it has found in gene therepy.

Repifermin is made by a human gene called keatinocyte growth factor-2, or KGF-2.

HGS granted a joint development and promotion option to SmithKline in June 1996. The two companies have agreed to share the costs of phase III as well as development costs beyond those studies. The two sides are in the process of negotiating a definitive agreement, HGS said in a statement.

Repifermin is currently the subject of three phase II clinical trials.

HGS shares closed at $81-1/2 in Friday`s Nasdaq trading, up $2-5/8 from the previous close. Shares reached a 52-week high of $116-3/8 in March and a 52-week low of $17-13/16 in Oct 1999. Rtr 05:13 10-16-00



May they are only looking for a reason to buy :-)

[estephan]

Falls es jemand noch etwas genauer wissen will .......

Human Genome Sciences and Smithkline Beecham Agree to Jointly Develop and Commercialize Repifermin, an HGS Product

PR Newswire
Monday October 16 4:45am

Repifermin is in Multiple Clinical Trials Conducted By HGS For Wound Care, Mucositis and Inflammatory Bowel Disease

ROCKVILLE, Md., Oct. 16 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that SmithKline Beecham Corporation has exercised its first co-right option to jointly develop and commercialize repifermin, a novel growth factor discovered and currently being developed by HGS.

Repifermin, also known as Keratinocyte Growth Factor-2, or KGF-2, is a novel protein with potential therapeutic applications in wound care, including venous stasis ulcers, diabetic ulcers, and pressure ulcers, as well as oral and intestinal mucositis, and inflammatory bowel diseases, such as ulcerative colitis and Crohn`s disease. HGS recently announced the positive results of its first Phase II trial in venous ulcers and its plans to move forward with a large efficacy and safety trial.

As part of its June 1996 Agreement with SmithKline Beecham, HGS granted a 50/50 co-development and co-promotion option to SmithKline Beecham for HGS` human therapeutic products that successfully complete Phase IIa clinical trials. Clear to both parties at signing was that some products discovered by HGS with significant commercial potential would require the support of a successful large company with the expertise and infrastructure to maximize sales and profitability. Repifermin is the first HGS-discovered drug to be offered to SmithKline Beecham. HGS and SmithKline Beecham are now negotiating a definitive agreement to allocate responsibilities and resources. Unless otherwise agreed by both parties, SB and HGS will share equally in clinical development costs at Phase III and beyond.

"We are delighted that SmithKline Beecham has selected HGS` first protein for co-development and co-promotion," said William A. Haseltine, Ph.D., Chairman and Chief Executive Officer of Human Genome Sciences. "We are pleased that they share our enthusiasm for this protein and its potential. This is a significant collaboration for our company and for the field of genomics-based drug discovery. SB`s participation and funding of future trials will enhance the promise of repifermin and allow HGS to allocate resources to other product opportunities in its pipeline."

Arthur M. Mandell, Senior Vice President, Corporate and Business Development of Human Genome Sciences, commented, "We are very pleased to have the opportunity to collaborate with SmithKline Beecham to further develop and later commercialize repifermin. Because the disease areas of interest reflect large unsatisfied market opportunities, our combined efforts should be beneficial to both parties. The profile of repifermin allows this drug to have possible utility in many important indications."

Repifermin is currently the subject of three Phase II clinical trial programs. In a topical formulation, repifermin is being evaluated in the treatment of chronic venous stasis ulcers. Additionally, repifermin is being administered systemically in two distinct indications. One trial is evaluating repifermin`s safety and ability to prevent mucositis when administered to patients undergoing chemotherapy with bone marrow transplantation. The second trial is evaluating repifermin`s safety and activity when administered to patients with active ulcerative colitis, the most common form of inflammatory bowel disease.

Human Genome Sciences is a company with the mission to treat and cure disease by bringing new gene-based drugs to patients.

HGS and Human Genome Sciences are registered trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the company`s web site at www.hgsi.com . Copies of HGSI press releases are also available by fax 24 hours a day at no charge by calling 800/758-5804, ext. 121115.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences` current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the company`s unproven business model, dependence on new technologies, uncertainty as to clinical trial results, ability to develop and commercialize products, dependence on collaborators for services and revenue, substantial indebtedness, intense competition, uncertainty of patent and intellectual property protection, dependence on key management, uncertainty of regulation of products, dependence on key suppliers and other risks that may be described in the company`s filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today`s date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

Source: Human Genome Sciences, Inc.
Contact: William A. Haseltine, Ph.D., Chairman and Chief Executive Officer; or Kate de Santis, Director, Corporate Communications and Investor Relations, 301-309-8504; both of Human Genome Sciences


Source: PR Newswire
Quelle: stockmaster.com